📊 Interactive Cash Flow Visualizations
Sankey Diagram: Source & Application
Waterfall Chart: Net Movement
📈 Key Financial Parameters
| Parameter | Value |
|---|---|
| Capital expenditures | 121 |
| Cash and cash equivalents, end of year | 683 |
| Depreciation and amortization | 116 |
| EBITDA | 1291 |
| Gross Profit | 2627 |
| Income tax provision | 276 |
| Interest-net | 1567 |
| Long-term debt, excluding current maturities | 6166 |
| Net Earnings | 899 |
| Net Sales | 4184 |
| Operating income | 1175 |
| Profit before tax | 1175 |
| Total Assets | 88990 |
| Total Equity | 7180 |
| Total current assets | 1073 |
| Total current liabilities | 0 |
| Total liabilities and Equity | 88990 |
🧮 Calculated Metrics
| Metric | Value |
|---|---|
| Cost of Debt | 0.2541 |
| Cost of Equity | 0.1089 |
| Total Debt and Equity | 13,346 |
| EBIT | 1,175 |
| tax rate | 0.0448 |
| Net working capital | 1,073 |
| FCF0 | 2,190.4051 |
| FCF1 | 2,234.2132 |
| FCF2 | 2,278.8975 |
| WACC | 0.1707 |
| Terminal Value | 15,419.9341 |
| Enterprise Value | 14,821.1593 |
| Equity value | 9,338.1593 |
| Intrinsic Share price | 63.1426 |
📝 Detailed Cashflow Breakdown
| Line Item | Value |
|---|---|
| Closing Cash and cash equivalents, end of year | 683 |
| Net (decrease)/increase in cash and cash equivalents | 32 |
| Net cash provided by operating activities | 1073 |
| Net cash provided by/(used in) financing activities | -1779 |
| Net cash used in investing activities | 738 |
| Opening Cash and cash equivalents, beginning of year | 651 |
🔍 Management Commentary & Qualitative Insights
Q: Analyze the auditor’s assessment of Internal Control over Financial Reporting (ICFR). Were any material weaknesses or significant deficiencies identified?
No material weaknesses or significant deficiencies were identified; management concluded internal control over financial reporting was effective, and the auditor's opinion corroborates this.
Q: Are there any issues like pending lawsuits (contingent liabilities)?
Yes, there are pending civil cases such as Lifescan Inc. and Johnson & Johnson Health Care Services v. Jeffrey C. Smith, et al., and Roche Diagnostics and Roche Diabetes Care Inc. v. Jeffrey C. Smith, et al., with trials scheduled for April 2027; potential liabilities are being assessed.
Q: Does the auditor's report mention any material uncertainty related to going concern? Identify any language suggesting the company might not survive the next 12 months.
Not Found
Q: Extract the Auditor's Report section. Does the auditor provide an unqualified opinion? If the opinion is modified (qualified, adverse, or a disclaimer), explain the specific reasons provided by the auditor for this modification.
The auditor provides an unqualified opinion; no modification is noted, so no specific reasons for modification are given.
Q: Is the revenue growth sustainable?
Not Found
Q: List the Key Audit Matters (KAMs) identified by the auditor. For each, summarize why the auditor considered it a significant risk and what specific procedures they performed to address it.
Key Audit Matter: Allowance for loan and lease losses. The auditor deemed it a significant risk due to the complexity and judgment involved in estimating expected credit losses, including weighting of economic scenarios and qualitative adjustments. Procedures included obtaining an understanding of the ALLL governance process, testing controls over model development and data, performing analytical procedures and sensitivity analyses on scenario weightings, evaluating the completeness of qualitative adjustments, and assessing consistency with historical loss data and peer benchmarks.
Q: What are the biggest risks ahead?
Macroeconomic conditions, interest‑rate volatility, regulatory changes, competition from fintechs and other non‑traditional financial institutions, cybersecurity threats, fraud, litigation, and regulatory enforcement actions.
Q: What are the competitive advantages that protect the business from rivals?
Quality of service, deep understanding of local communities, extensive branch network, breadth of product offerings and strong customer relationships.
Q: What are the details on Executive Compensation and "Promoter Pledging"?
Executive compensation includes share‑based compensation expense of $35 million in 2025, stock option exercises, restricted stock and RSU grants, and related tax benefits; no mention of promoter pledging.
Q: What are the key insights from the Management Discussion and Analysis report?
MD&A provides analysis of financial condition, capital adequacy, liquidity, risk management and operating segment results, highlighting capital ratios, stress‑testing outcomes, liquidity sources and regulatory developments.
Q: What are the key insights on the expansion of the product portfolio?
The product portfolio is expanded through commercial banking, capital markets, commercial real‑estate lending, retail banking, and wealth‑management services, with an emphasis on local authority, digital channels and new offerings such as risk‑management and underwriting.
Q: What is the company's stated future outlook and growth strategy?
The company describes its future outlook through forward‑looking statements that set expectations for continued growth, capital management and strategic initiatives, but does not detail a specific growth strategy.
Q: What is the core revenue model, key products, and major customers?
Core revenue model: net interest income and noninterest income. Key products: commercial and small‑business banking, capital markets, CRE lending, retail banking and wealth‑management services. Major customers: not identified in the text.
Q: Who is the CEO and Chairman of the Company?
HARRIS H. SIMMONS
Q: what is the "Operating Cash Flow" and is it growing?
Decreased from 1148 in 2024 to 1073 in 2025
Comments 0